ArticleAnnals of African medicine2026
Allopurinol-associated Drug Reaction with Eosinophilia and Systemic Symptom Syndrome: A Severe Delayed Drug Hypersensitivity Reaction.
Article in Annals of African medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
abstractDRESS syndrome is a rare and life-threatening adverse drug reaction that usually presents with delayed onset rash, Hematalogical abnormality, and multiorgan involvement. In patients with renal impairment, allopurinol is most frequently associated with this syndrome. We report an elderly male in his early 60's presented with a 35 day history of generalized maculopapular rash with vesicles, scaling, and facial swelling, starting 3-4 weeks after initiating allopurinol (100mg daily) for gout. His medical history includes chronic kidney disease. Using the RegiSCAR scoring system, we confirmed DRESS syndrome. Allopurinol was discontinued immediately, and systemic corticosteroid therapy was started. Patient clinical and laboratory parameters improved progressively, and in 6 weeks, symptoms completely resolved. This case highlights that Clinicians should be extra vigilant in high-risk populations, especially in renal-impaired patients, while prescribing allopurinol.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.